AIV Logo AIV Assistant

Loading...

Logo Cartesian Therapeutics, Inc. - RNAC Open Cartesian Therapeutics, Inc. in new tab

7.87 USD
EPS
-0.68
P/B
-82.27
Target Price
36.43 USD

7.8700 USD

7.870 USD

Daily: +0.00%
Key Metrics

Earnings date: March 12, 2026

EPS: -0.68

Book Value: -0.10

Price to Book: -82.27

% Insiders: 59.849%

Growth

Revenue Growth: -0.99%

Earnings Growth: -0.07%

Estimates

Forward P/E: -2.29

Forward EPS: -3.49

Target Mean Price: 36.43

DCF Valuation

Tweak assumptions to recompute fair value for Cartesian Therapeutics, Inc. (RNAC)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Logo About Cartesian Therapeutics, Inc. - (RNAC)

Website: https://www.cartesiantherapeutics.com

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 5, 2024 0.030000
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion